PRESS RELEASE

Dessel, October 30, 2026

Belgoprocess and PanTera Join Forces to Produce Innovative Cancer Therapy: New Operational and Strategic Milestones

In the fight against cancer, Belgium's nuclear technology sector and the nuclear industry are once again making significant progress. Last week, Belgoprocess and PanTera reached two important milestones in their collaboration. Belgoprocess has successfully begun opening a new batch of thorium-229 (Th-229) capsules sourced from PanTera's international partner, while both organizations also signed a long-term agreement for the purification of PanTera's radium. This collaboration strengthens Belgium's position as a global leader in innovation in nuclear medicine.

Long-Term Partnership for Radium Purification

On October 30, 2026, Belgoprocess and PanTera signed a strategic agreement for the purification of radium. PanTera holds the right to use a significant quantity of pure radium that has been stored at SCK CEN for more than 40 years. This radium will be used in PanTera's state-of-the-art Actinium Production Center (APC), which is currently under construction in Mol. Because it has been stored for so long, the impurities that have accumulated in it must be removed, preferably before PanTera's facility becomes operational and Belgoprocess was selected for this task. Thanks to this contract, PanTera ensures the immediate availability of high-purity radium as a raw material at the start of its large-scale commercial production of actinium-225, which is expected to begin in 2029.

Successful Opening of Th-229 Capsules

The decay of thorium-229 produces radium-225, which itself decays into actinium-225, thereby enabling PanTera to make early deliveries of actinium-225 for clinical studies, PanTera's so called "early supply route." To this end, Belgoprocess has successfully begun opening a new batch of Th-229 capsules at its nuclear facilities in Dessel; these capsules were supplied by PanTera's international partner. This process requires specialized nuclear expertise and infrastructure.

Belgoprocess had already opened an initial batch of Th-229 capsules last year on behalf of PanTera. By further expanding the available supply of Th-229, PanTera is strengthening its current production capacity and supporting the growing demand for Ac-225 for clinical development and future commercial applications. Next year, additional capsules will be opened at the Institut des RadioÉléments (IRE) in Fleurus, which will also produce actinium-225 on behalf of PanTera. This additional inventory makes Belgium the largest source of actinium-225 in Europe and contributes to a more robust and sustainable global supply chain for this crucial medical radioisotope.

The successful execution of this operation underscores the complementary nature of both organizations: Belgoprocess brings unique expertise and infrastructure for the safe handling of radioactive materials, combined with PanTera's ambition to become a leading global supplier of Ac-225.

Quote from Sven Van Den Berghe, CEO of PanTera:

"The collaboration with Belgoprocess is invaluable to our mission. Through the successful processing of the Th-229 capsules and the signing of this contract for radium purification, we are taking a crucial step toward the industrial upscaling of Ac-225. This brings us closer to our goal of helping tens of thousands of cancer patients worldwide every year."

Quote from Wim Van Laer, CEO of Belgoprocess:

"At Belgoprocess, we are proud to be able to apply our unique expertise in nuclear processing and waste and materials management to innovative medical applications such as this one. This agreement reaffirms our key role as a reliable partner in the nuclear supply chain, serving society."

With these new milestones, PanTera and Belgoprocess reaffirm the strategic role of the nuclear ecosystem in the Mol-Dessel region. By combining expertise in radioisotope production, nuclear processing, and materials management, both organizations are continuing to build a reliable European supply chain for medical radioisotopes that play a key role in the fight against cancer.

About PanTera

PanTera originated as a joint venture between IBA and SCK CEN, established to secure the large-scale production of actinium-225 (Ac-225), a promising alpha-emitting radioisotope for targeted cancer therapies. With a Series A funding of €95.6 million and all necessary building blocks available, PanTera is ideally positioned to develop cutting-edge production capabilities to enable the accessibility of innovative cancer treatments based on Ac-225.

PanTera's production strategy is built on two complementary approaches: an Early Supply production leveraging Thorium-229 decay, which is providing Ac-225 since May 2025, and a Commercial Supply production utilizing the Ra-226 photonuclear reaction to enable large-scale commercial production by 2029. These initiatives ensure a sustainable and scalable supply chain to meet the growing global demand for Ac-225.

For more information, see: www.pantera-life.com

About Belgoprocess

Belgoprocess is an expert in the treatment of radioactive waste and the decommissioning of nuclear facilities in Belgium. From its base in Dessel, the company contributes daily to nuclear safety and makes its advanced facilities and decades of experience available for industrial and societal projects within the nuclear sector.

For more information, see: www.belgoprocess.be

Press Contact

Belgoprocess	PanTera
Bart Thieren	Natacha Sweert
Spokesperson	Commercial Account & Marketing Manager
+32 478 20 14 17	+32 460 96 17 26
bart.thieren@belgoprocess.be	natacha.sweert@pantera-life.com
